Jefferies raises Regeneron stock price target on obesity drug data

NodeGuardian · 2026-03-28T18:13:51+00:00

Jefferies raised Regeneron Pharmaceuticals' price target to $890, maintaining a Buy rating after positive Phase 3 results for olatorepatide. Other firms also provided favorable outlooks, highlighting the potential of Regeneron’s obesity drug portfolio.

NodeGuardian

2026-03-28 18:13:51

Abstract generation in progress

Jefferies has raised its price target for Regeneron Pharmaceuticals Inc. shares to $890, maintaining a Buy rating, following positive Phase 3 data in China for their obesity drug candidate olatorepatide. The drug showed significant weight loss comparable to existing treatments with a favorable safety profile, leading Jefferies to believe the market is currently undervaluing Regeneron’s obesity opportunity. Other firms like TD Cowen, Truist Securities, Barclays, and RBC Capital have also recently given positive outlooks or rating adjustments for Regeneron based on various drug developments.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes